1. Search Result
Search Result
Results for "

RNase

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

1

Peptides

5

MCE Kits

3

Natural
Products

10

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-155583

    DNA/RNA Synthesis Infection
    RNase L-IN-1 (compound 17a) is an inhibitor of RNase L, or Ribonuclease L. RNase L degrades RNAs to prevent viral replication, and mediates the innate immune responses and inflammation .
    <em>RNase</em> L-IN-1
  • HY-155583A

    DNA/RNA Synthesis Infection
    RNase L-IN-1 (compound 17a) trihydrochloride is an inhibitor of RNase L or ribonuclease L. RNase L degrades RNA to prevent viral replication and mediates innate immune responses and inflammation .
    <em>RNase</em> L-IN-1 trihydrochloride
  • HY-E70098

    Others Cancer
    RNase H2 is the predominant source of RNase H activity in mammalian and human cells. RNase H2 protects genome integrity. RNase H2 has been associated with ribonucleotide removal from genomic DNA in yeast and mouse, where it is required for embryonic development .
    <em>RNase</em> H2
  • HY-129046A

    Others Others
    RNase A (10mg/mL, DNase free) is a ribonuclease used to catalyze RNA degradation without containing DNase. RNase A is often employed in cell cycle assay .
    <em>RNase</em> A (10mg/mL, DNase free)
  • HY-RS12018

    Small Interfering RNA (siRNA) Others

    RNASE1 Human Pre-designed siRNA Set A contains three designed siRNAs for RNASE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNASE1 Human Pre-designed siRNA Set A
    RNASE1 Human Pre-designed siRNA Set A
  • HY-RS12019

    Small Interfering RNA (siRNA) Others

    RNASE2 Human Pre-designed siRNA Set A contains three designed siRNAs for RNASE2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNASE2 Human Pre-designed siRNA Set A
    RNASE2 Human Pre-designed siRNA Set A
  • HY-RS12020

    Small Interfering RNA (siRNA) Others

    RNASE3 Human Pre-designed siRNA Set A contains three designed siRNAs for RNASE3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNASE3 Human Pre-designed siRNA Set A
    RNASE3 Human Pre-designed siRNA Set A
  • HY-RS12021

    Small Interfering RNA (siRNA) Others

    RNASE4 Human Pre-designed siRNA Set A contains three designed siRNAs for RNASE4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNASE4 Human Pre-designed siRNA Set A
    RNASE4 Human Pre-designed siRNA Set A
  • HY-RS12022

    Small Interfering RNA (siRNA) Others

    RNASE6 Human Pre-designed siRNA Set A contains three designed siRNAs for RNASE6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNASE6 Human Pre-designed siRNA Set A
    RNASE6 Human Pre-designed siRNA Set A
  • HY-RS12023

    Small Interfering RNA (siRNA) Others

    RNASE7 Human Pre-designed siRNA Set A contains three designed siRNAs for RNASE7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RNASE7 Human Pre-designed siRNA Set A
    RNASE7 Human Pre-designed siRNA Set A
  • HY-P0229

    RNase T1

    DNA/RNA Synthesis Others
    Ribonulease T1, Aspergillus oryzae (Rnase T1), is commonly used in biochemical research. Ribonuclease T1 is an endonuclease that can specifically degrade single stranded RNA. Ribonuclease T1 can form nucleoside 2 ', 3 '-cyclic phosphoric acid intermediates to cut the phosphodiester bond between 3' -guanosine residues and adjacent nucleoside 5 '-OH groups to produce 3' -GMP terminal oligonucleotides .
    Ribonulease T1, Aspergillus oryzae
  • HY-129046

    Ribonuclease A; EC 3.1.27.5; RNase A

    Others Others
    Ribonuclease A (EC 3.1.27.5) cleaves RNA 3′ to pyrimidines and actively cleaves RNA at every pyrimidine residue. Ribonuclease A catalyzes the hydrolysis of single stranded RNA in the absence of metal ions or cofactors .

    <em>RNase</em> A, bovine pancreas
  • HY-108882A

    Others Others
    Recombinant DNase I (RNase-free) is a recombinant deoxyribonuclease that degrades DNA. Recombinant DNase I is essential for limiting inflammatory responses and maintaining homeostasis .
    Recombinant  DNase I (<em>RNase</em>-free)
  • HY-N12387

    Others Infection
    Laccaic acid C is an potent inhibitor of RNase H with an IC50 of 8.1 μM. Laccaic acid C also inhibits viral proliferation in cell .
    Laccaic acid C
  • HY-145425

    IRE1 Cancer
    PAIR2 is a potent and selective partial antagonist of IRE1α RNase. PAIR2 can completely occupy IRE1α’s ATP-binding site in cells and block the ability of a potent KIRA to inhibit XBP1 splicing .
    PAIR2
  • HY-139212

    IRE1 Others
    IXA6 is a novel IRE1/XBP1s activator, and can induce IRE1 RNase activity .
    IXA6
  • HY-150759

    HIV Infection
    HIV-1 inhibitor-45 (compound IA-6) is a potent HIV-1 RNase H inhibitor with an IC50 value of 0.067 μM. HIV-1 inhibitor-45 shows an antiviral activity .
    HIV-1 inhibitor-45
  • HY-113767

    Others Metabolic Disease
    Momordin II, an oleanane-type triterpene glycoside, is a ribosome inactivating protein. Momordin II inhibits cell-free protein synthesis, releases adenine from rat liver ribosomes and from DNA, and has no RNase activity .
    Momordin II
  • HY-132580

    BIIB067; ISIS-SOD1Rx

    DNA/RNA Synthesis Neurological Disease
    Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce the synthesis of SOD1 protein. Tofersen can be used for the research of amyotrophic lateral sclerosis (ALS) .
    Tofersen
  • HY-17624

    Neomycin B; Fradiomycin B

    Bacterial Antibiotic Infection
    Framycetin (Neomycin B), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections .
    Framycetin
  • HY-17624A

    Neomycin B sulfate; Fradiomycin B sulfate

    Antibiotic Bacterial Infection
    Framycetin sulfate (Neomycin B sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Framycetin sulfate competes for specific divalent metal ion binding sites in RNase P RNA. Framycetin sulfate inhibits hammerhead ribozyme with a Ki of 13.5 μM. Framycetin sulfate, a 5″-azido neomycin B precursor, binds the Drosha site in miR-525 and is used for hepatic encephalopathy and enteropathogenic E. coli infections .
    Framycetin sulfate
  • HY-D0846

    Biochemical Assay Reagents Neurological Disease
    Diethyl pyrocarbonate is a potent, orally active, non-specific chemical inhibitor of RNase. Diethyl pyrocarbonate has been useful in vitro as an agent relatively specific for binding to imidazole of histidine. Diethyl pyrocarbonate inhibits central chemosensitivity in rabbits. Diethyl pyrocarbonate can modify Ser, Thr, His and Tyr residues. Diethyl pyrocarbonate can be used for modeling .
    Diethyl pyrocarbonate
  • HY-W028350

    HIV DNA/RNA Synthesis Infection
    NSC727447 is an inhibitor of ribonuclease H (Rnase H) of HIV-1 and HIV-2. NSC727447 has little activity against E. coli RNase H, but great selectivity over human Rnase H, with IC50s value of 2.0 μM, 2.5 μM, 100 μM, 10.6 μM, respectively .
    NSC727447
  • HY-107400
    B I09
    1 Publications Verification

    IRE1 Cancer
    B I09 is an IRE-1 RNase inhibitor, with an IC50 of 1230 nM.
    B I09
  • HY-154828

    3′,5′-UDP

    DNA/RNA Synthesis Others
    Uridine 3′,5′-diphosphate (3′,5′-UDP; Compound pUp) is a competitive RNase inhibitor .
    Uridine 3′,5′-diphosphate
  • HY-114368A

    AMG-18 Hydrochloride

    IRE1 Inflammation/Immunology
    Kira8 Hydrochloride (AMG-18 Hydrochloride) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM .
    Kira8 Hydrochloride
  • HY-114368
    Kira8
    5+ Cited Publications

    AMG-18

    IRE1 Inflammation/Immunology
    Kira8 (AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM .
    Kira8
  • HY-19708
    KIRA6
    10+ Cited Publications

    IRE1 Metabolic Disease Inflammation/Immunology Cancer
    KIRA6 is an advanced small-molecule IRE1α RNase kinase inhibitor with an IC50 of 0.6 µM . KIRA6 can trigger an apoptotic response .
    KIRA6
  • HY-124646

    IRE1 Inflammation/Immunology
    KIRA-7, an imidazopyrazine compound, binds the IRE1α kinase (IC50 of 110 nM) to allosterically inhibit its RNase activity. KIRA-7 has an anti-fibrotic effect .
    KIRA-7
  • HY-104040
    MKC8866
    5+ Cited Publications

    Orin1001

    IRE1 Cancer
    MKC8866, a salicylaldehyde analog, is a potent, selective IRE1 RNase inhibitor with an IC50 of 0.29 μM in human vitro. MKC8866 strongly inhibits Dithiothreitol-induced X-box-binding protein 1-spliced (XBP1s) expression with an EC50 of 0.52 μM and unstresses RPMI 8226 cells with an IC50 of 0.14 μM . MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibits prostate cancer (PCa) tumor growth .
    MKC8866
  • HY-U00459
    GSK2850163
    3 Publications Verification

    IRE1 Cancer
    GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively.
    GSK2850163
  • HY-U00459B

    IRE1 Cancer
    GSK2850163 hydrochloride is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α) which can inhibit IRE1α kinase activity and RNase activity with IC50s of 20 and 200 nM, respectively.
    GSK2850163 hydrochloride
  • HY-132572

    HIV Infection
    HIV-1 integrase inhibitor 9 (compound 8a) is a potent HIV-1 RNase H inhibitor with an IC50 of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity .
    HIV-1 integrase inhibitor 9
  • HY-17537
    APY29
    5+ Cited Publications

    IRE1 Cancer
    APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC50 of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain .
    APY29
  • HY-N10776

    HIV Infection
    Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside is a glucopyranoside. Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside inhibts HIV-2 RNase H with an IC50 value of 5.19 μM .
    Kaempferol-3-O-(6′′-galloyl)-β-glucopyranoside
  • HY-10255A
    Sunitinib
    Maximum Cited Publications
    46 Publications Verification

    SU 11248

    VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
    Sunitinib
  • HY-10255
    Sunitinib Malate
    Maximum Cited Publications
    46 Publications Verification

    SU 11248 Malate

    PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
    Sunitinib Malate
  • HY-153713

    c-Myc Apoptosis Cancer
    MYC-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) to MYC internal ribosome entry site (IRES).MYC-RIBOTAC contains a MYC mRNA-binder and a small molecule that recruits and locally activates RNase L1 and decreases the mRNA and protein expression levels of MYC, induces apoptosis. MYC-RIBOTAC can be used for anticancer research .
    MYC-RIBOTAC
  • HY-10255AS

    SU 11248-d10

    Sunitinib-d10 is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].
    Sunitinib-d10
  • HY-10255AS1

    Isotope-Labeled Compounds VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib-d4 is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].
    Sunitinib-d4
  • HY-U00460

    IRE1 Cancer
    3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer .
    3,6-DMAD hydrochloride
  • HY-136735

    IRE1 Neurological Disease Cancer
    IRE1α kinase-IN-1 is a highly selective IRE1α (ERN1) inhibitor, with an IC50 of 77 nM. IRE1α kinase-IN-1 displays 100-fold selectivity for IRE1α over the IRE1β isoform. IRE1α kinase-IN-1 inhibits ER stress-induced IRE1α oligomerization and autophosphorylation, and also inhibits IRE1α RNase activity (IC50=80 nM) .
    IRE1α kinase-IN-1
  • HY-U00460B

    IRE1 Cancer
    3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer .
    3,6-DMAD dihydrochloride
  • HY-145422

    IRE1 Apoptosis Others
    KIRA9 is a potent IRE1 inhibitor (IC50=4.8 μM in INS-1 cells). KIRA9 is able to fully engage the ATP-binding site of IRE1α. KIRA9 can block ER-localized mRNA decay and apoptosis .
    KIRA9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: